In an open‑label trial of 27 treatment‑resistant depression patients given a single 25 mg psilocybin dose with psychotherapy, those who had discontinued antidepressants before treatment showed comparable reductions in clinician‑rated and self‑reported depression, anxiety and suicidality to patients unmedicated at screening. Both groups experienced clinically significant improvements and similar intensity of psychedelic experience, suggesting medication tapering did not alter short‑term antidepressant effects in this sample.
- Published
- Journal
- Canadian Journal of Psychiatry
- Authors
- Chisamore, N., Kaczmarek, E. S., Doyle, Z., Johnson, D. E., Weiglein, G., Meshkat, S., Brudner, R. M., Blainey, M. G., Riva-Cambrin, J., Mcintyre, R. S., Rosenblat, J. D.